DDReg Pharma
DDReg Knowledge Capsule
🎧 DDReg Knowledge Capsule Welcome to the DDReg Knowledge Capsule — your go-to podcast for concise, insightful conversations on the latest trends, innovations, and challenges in the life sciences industry. Brought to you by the experts at DDReg, this series distills complex regulatory affairs, pharmacovigilance, market access, and clinical development topics into easy-to-understand episodes. Subscribe now and empower your pharma journey, one capsule at a time.
Be sure to visit the podcast's website and support the creator: www.ddregpharma.com
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
French Pharma Registration: ANSM, CTD Dossiers & Market Access 20.11.2026 20:59
Welcome to the DDReg Knowledge Capsule! In this episode, we explore pharmaceutical registration and market access in France. Learn about the four ANSM approval pathways (Centralised, DCP, MRP, and National), CTD dossier & French language rules, and how pricing and reimbursement differ from regulatory authorization. For more info. read our blog: https://www.ddregpharma.com/blogs/drug-registrati...
Drug Registration in UK & MHRA Pathways 17.11.2026 21:24
Welcome to the DDReg Knowledge Capsule! In this episode, we outline how foreign pharmaceutical companies can successfully navigate the UK's MHRA drug registration pathways. Discover how to leverage the International Recognition Procedure (IRP) for faster approvals, understand national evaluation timelines, and ensure ongoing compliance with UK representation and pharmacovigilance standards. For Mo...
Navigating Israel's 70 & 120-Day Fast-Track Drug Approvals 06.11.2026 26:02
In this episode, we break down the Israel Ministry of Health (MOH) 2025 Drug Registration Reform and what foreign pharmaceutical companies must know to successfully enter the Israeli market. We examine the 70-day and 120-day reliance evaluation pathways, detailing how prior authorisations from recognised foreign regulatory agencies (such as the FDA, EMA, MHRA, Health Canada, and TGA) can streamlin...
Drug Registration in Spain: AEMPS Process & 2026 Timeline 03.11.2026 14:01
What does it take to successfully register a medicine in Spain in 2026? In this episode, we dive into the Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) national procedure, the 210-day assessment timetable, and how to bridge the gap between approval and commercial launchLearn more: https://resource.ddregpharma.com/blogs/drug-registration-spain-aemps-national-procedure/
Winning AIFA Drug Reimbursement in Italy: Regulatory & HTA Roadmap 29.10.2026 19:07
Navigating pharmaceutical launch in Italy requires far more than securing European or national marketing authorization. In this episode of the DDReg Knowledge Capsule, we break down the critical regulatory and Health Technology Assessment (HTA) steps required by the Italian Medicines Agency (AIFA) to achieve pricing, reimbursement, and patient access. For more info read our blog: https://resource....
Navigating EMA’s Voluntary Data Submission Pilot for NAMs 28.10.2026 20:04
Welcome to the DDReg Knowledge Capsule! In this episode, we unpack the EMA’s Voluntary Data Submission pilot for New Approach Methodologies (NAMs). Learn how drug sponsors and researchers can submit non-animal testing evidence for informal regulatory feedback, understand essential briefing package requirements, and explore how this initiative compares with FDA and MHRA frameworks. For more info re...
Navigate German Nutraceutical & Novel Food Compliance 23.10.2026 22:25
When does a nutraceutical ingredient become a Novel Food regulatory concern? 🌿 Explore Germany’s nutraceutical market, EU Novel Food regulations, ingredient approval requirements, and key compliance challenges for businesses.🎧 Tune in for insights into nutraceutical registration and regulatory compliance.#Nutraceuticals #NovelFood #Germany #FoodRegulations #RegulatoryAffairs For more info read o...
Japan & Malaysia: Faster Clinical Trial Approvals? 🌏 21.10.2026 21:25
Can regulatory reliance accelerate clinical trial approvals in Japan and Malaysia? Discover how the new pilot could streamline regulatory reviews, reduce timelines, and shape the future of clinical research.🎧 Tune in for insights on clinical trial regulations and global regulatory strategy.#ClinicalTrials #RegulatoryAffairs #Japan #Malaysia #ClinicalResearchFor more info read our blog: https://re...
Global-to-Local Pharmacovigilance: Bridging Safety Gaps 19.10.2026 21:53
How can Marketing Authorization Holders (MAHs) prevent gaps between global and local safety teams? 🌍 Discover key strategies for stronger pharmacovigilance governance, effective communication, and regulatory compliance.🎧 Tune in to explore smarter safety coordination and risk management.#Pharmacovigilance #DrugSafety #PatientSafety #RegulatoryAffairsTo know more read our blog: https://resource.d...
Realities of EAEU Pharmaceutical Registration 17.10.2026 25:57
Welcome to DDReg Knowledge Capsule! In this episode, we unpack the complexities of pharmaceutical registration across the Eurasian Economic Union (EAEU)—covering Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan. While the EAEU Unified Procedure establishes a harmonised regional pathway for multi-state marketing authorisations, obtaining approval and maintaining post-market compliance still req...
Medical Device Registration in Kenya: Beyond Approval 16.10.2026 17:48
Entering Kenya’s medical device market? 🌍 Discover the key regulatory requirements foreign manufacturers need to know beyond product registration, including local representation, importation, compliance, and post-market obligations. To know more about the Podcast Read our Blog: https://resource.ddregpharma.com/blogs/medical-device-registration-kenya-foreign-manufacturers/
Dietary Supplement Registration in Brazil vs. Mexico ANVISA and COFEPRIS Market Entry Pathways 13.10.2026 24:12
"Welcome to the DDReg Knowledge Capsule" — This episode explores the contrasting regulatory pathways for entering the dietary supplement markets in Brazil and Mexico. It compares ANVISA's mandatory notification system in Brazil with COFEPRIS's compliance-focused framework in Mexico, detailing essential requirements for product classification, ingredient eligibility, local labeling rules, and impor...
Strategic Regulatory Intelligence: Turning Regulatory Signals into Product Decisions 12.10.2026 20:35
DDReg Knowledge Capsule, discover how pharmaceutical leaders move beyond passive regulatory monitoring to build a decision-oriented strategy that directly shapes product development. Learn how evaluating global health authority updates through product-specific context enables teams to assess impacts across clinical trials, CMC, dossier submissions, and post-approval lifecycles—ensuring every strat...
South Korea KDMF Requirements for Imported APIs 09.10.2026 21:59
Welcome to the DDReg Knowledge Capsule" — This episode provides a practical overview of South Korea's Korea Drug Master File (KDMF) registration framework managed by the Ministry of Food and Drug Safety (MFDS) for imported active pharmaceutical ingredients (APIs). It explains how to determine registration scope, adapt global technical packages (such as US DMFs, ASMFs, or CEPs) to satisfy Korean re...
Regulatory Data Quality: The Hidden Risk Behind Submission & Compliance 07.10.2026 22:39
Regulatory success depends on more than an accurate dossier. In today’s data-driven pharmaceutical environment, inconsistent product information across submissions, labeling, regulatory databases, and lifecycle activities can create submission delays, regulatory queries, rework, and compliance risks. In this episode, we explore why Regulatory Data Quality has become a critical priority for pharmac...
Pharmacovigilance Launch Readiness For Marketing Authorization Holders 01.10.2026 22:46
Welcome back to the DDReg Knowledge Capsule! In this episode, we explore how Marketing Authorization Holders (MAHs) build and maintain compliant Pharmacovigilance (PV) governance structures as products transition to commercialization. We break down the core operational components of PV systems, including Qualified Person for Pharmacovigilance (QPPV) services, Individual Case Safety Report (ICSR) p...
The Strategic Role of Regulatory Affairs in Pharma Industry 29.09.2026 21:01
In this edition of the DDReg Knowledge Capsule, we explore how Regulatory Affairs guides medicinal products from early research through market authorization and post-approval lifecycle management. Learn how RA teams establish global regulatory strategies, coordinate complex submissions, manage health authority interactions, and leverage digital tools to accelerate approval timelines while maintain...
Global Biosimilar Pathways 2026 : US, EU, UK & Asia 24.09.2026 18:48
Welcome to the DDReg Knowledge Capsule! In this episode, we unpack the rapidly changing global regulatory landscape for biosimilar development across key target markets: the US (FDA), European Union (EMA), UK (MHRA), China (NMPA/CDE), and Japan (PMDA).We examine the pivotal 2026 transition away from routine comparative clinical efficacy trials toward tailored, risk-based evaluation frameworks grou...
Registering Biosimilar Drugs with Health Canada 23.09.2026 11:29
Welcome to DDReg Knowledge Capsule! In this episode, we explore Health Canada's regulatory framework for registering biosimilar biologic drugs. We break down the fundamental differences between biosimilars and generic small-molecule drugs, explain why biosimilars are authorized through the New Drug Submission (NDS) pathway, and discuss the pivotal role of the Canadian Reference Biologic Drug (CRBD...
Global Regulatory Operating Model For Pharma Leaders 18.09.2026 21:28
This episode explores how pharmaceutical organisations can effectively structure regulatory roles across global, regional, and local markets. Based on the DDReg guide to global regulatory operating models, the discussion highlights the strategy of "controlled decentralization"—maintaining global consistency for core scientific positions while ensuring local authority ownership where jurisdiction-s...
Mastering Global CMC Variations & Life Cycle Management 11.09.2026 22:31
Welcome to DDReg Knowledge Capsule! In this episode, we dive into the complex world of global post-approval change management in the pharmaceutical industry. When a drug product undergoes a single internal scientific or manufacturing modification—such as a site transfer, process modification, or analytical method update—it can trigger dozens of distinct regulatory submissions across international...
Malaysia NPRA 2026: Fast Route for Biosimilar Registration 04.09.2026 22:59
Welcome to the DDREG Knowledge Capsule. In this episode, we unpack the National Pharmaceutical Regulatory Agency's (NPRA) landmark 2026 reliance pilot pathway in Malaysia. We explore how eligible biosimilars with prior US FDA or EMA approval can now access an accelerated 60-working-day registration timeline. However, this rapid timeline is far from automatic. We break down the strict parameters sp...
Mandatory EUDAMED Compliance for German Medical Devices 2026 31.08.2026 21:46
Welcome to this episode of the DDReg Knowledge Capsule. In this session, we break down Germany's critical regulatory transition from the national DMIDS database to the EU-wide EUDAMED platform. We explore the operational modules that became mandatory on 28 May 2026—including Actor Registration, UDI/Device Registration, Notified Bodies & Certificates, and Market Surveillance—and clarify the upc...
India's Pharma Shift from Generics to Innovation 27.08.2026 18:00
India is evolving from "the pharmacy of the world" to a powerhouse of pharmaceutical innovation, focusing on biosimilars, complex generics, and advanced therapies. In this episode, we unpack how this transition is fundamentally reshaping global regulatory strategies, clinical trial expectations, and FDA compliance for companies targeting international marketsVisit our blog for more: https://resour...
Why Gene Therapy Manufacturing Fails FDA 21.08.2026 17:44
Why do even the most revolutionary gene therapies with promising clinical results face critical roadblocks on their path to commercial approval? In this episode of the DDReg Knowledge Capsule, we delve deep into the core reasons behind Biologics License Application (BLA) delays, focusing on common Chemistry, Manufacturing, and Controls (CMC) pitfalls, weak analytical strategies, and limited compar...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.